 Joshua Thurman
Concepts (607)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 41 | 2023 | 288 | 11.840 |
Why?
| | Complement Activation | 59 | 2023 | 343 | 11.280 |
Why?
| | Kidney Diseases | 23 | 2023 | 354 | 9.460 |
Why?
| | Complement Pathway, Alternative | 34 | 2022 | 114 | 6.800 |
Why?
| | Complement Factor H | 16 | 2022 | 60 | 5.360 |
Why?
| | Complement Inactivating Agents | 13 | 2023 | 41 | 5.000 |
Why?
| | Kidney | 31 | 2023 | 1207 | 4.660 |
Why?
| | Kidney Glomerulus | 15 | 2023 | 102 | 4.480 |
Why?
| | Reperfusion Injury | 15 | 2019 | 254 | 4.240 |
Why?
| | Complement Factor B | 25 | 2023 | 100 | 4.030 |
Why?
| | Glomerulonephritis | 9 | 2023 | 45 | 3.950 |
Why?
| | Complement C3 | 25 | 2023 | 190 | 3.090 |
Why?
| | Immunoglobulin M | 9 | 2023 | 254 | 3.070 |
Why?
| | Acute Kidney Injury | 12 | 2023 | 646 | 2.710 |
Why?
| | Glomerulosclerosis, Focal Segmental | 5 | 2022 | 29 | 2.690 |
Why?
| | Autoimmune Diseases | 8 | 2023 | 395 | 2.560 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 6 | 2023 | 18 | 2.170 |
Why?
| | Receptors, Complement | 11 | 2022 | 111 | 1.790 |
Why?
| | Kidney Tubules | 7 | 2012 | 107 | 1.760 |
Why?
| | Graft Rejection | 9 | 2019 | 533 | 1.760 |
Why?
| | Lupus Nephritis | 7 | 2021 | 52 | 1.750 |
Why?
| | Receptor, Anaphylatoxin C5a | 6 | 2018 | 28 | 1.670 |
Why?
| | Nephrosis, Lipoid | 2 | 2022 | 10 | 1.620 |
Why?
| | Antibodies | 3 | 2019 | 374 | 1.610 |
Why?
| | Nephrotic Syndrome | 2 | 2022 | 25 | 1.600 |
Why?
| | Mice | 72 | 2023 | 15052 | 1.530 |
Why?
| | Animals | 102 | 2023 | 32104 | 1.510 |
Why?
| | Endothelial Cells | 5 | 2022 | 696 | 1.460 |
Why?
| | Complement C3b | 4 | 2023 | 30 | 1.440 |
Why?
| | Inflammation | 15 | 2021 | 2500 | 1.420 |
Why?
| | Epitopes | 8 | 2023 | 438 | 1.400 |
Why?
| | Immunosuppressive Agents | 6 | 2021 | 666 | 1.320 |
Why?
| | Mice, Knockout | 33 | 2022 | 2604 | 1.280 |
Why?
| | Complement Inactivator Proteins | 4 | 2021 | 40 | 1.240 |
Why?
| | Epithelial Cells | 9 | 2022 | 961 | 1.230 |
Why?
| | Complement C3d | 8 | 2023 | 60 | 1.220 |
Why?
| | Hemolytic-Uremic Syndrome | 4 | 2018 | 12 | 1.160 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1265 | 1.150 |
Why?
| | Mice, Inbred C57BL | 42 | 2022 | 4773 | 1.110 |
Why?
| | Contrast Media | 4 | 2018 | 369 | 1.110 |
Why?
| | Glomerulonephritis, Membranoproliferative | 3 | 2023 | 13 | 1.060 |
Why?
| | Complement Pathway, Classical | 3 | 2021 | 19 | 1.030 |
Why?
| | Humans | 95 | 2023 | 115739 | 1.020 |
Why?
| | Organ Transplantation | 2 | 2019 | 161 | 1.010 |
Why?
| | Thrombotic Microangiopathies | 4 | 2018 | 13 | 1.010 |
Why?
| | Complement C5a | 6 | 2018 | 59 | 1.010 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 58 | 1.010 |
Why?
| | Fluorescent Antibody Technique | 5 | 2021 | 398 | 0.970 |
Why?
| | Endothelium, Vascular | 5 | 2020 | 847 | 0.880 |
Why?
| | Nephritis | 2 | 2013 | 20 | 0.850 |
Why?
| | Lupus Erythematosus, Systemic | 8 | 2022 | 221 | 0.850 |
Why?
| | Kidney Transplantation | 8 | 2019 | 558 | 0.850 |
Why?
| | Antigen-Antibody Complex | 3 | 2020 | 88 | 0.850 |
Why?
| | Angiogenesis Inducing Agents | 2 | 2021 | 22 | 0.820 |
Why?
| | Magnetic Resonance Imaging | 5 | 2018 | 3122 | 0.810 |
Why?
| | Disease Models, Animal | 29 | 2021 | 3580 | 0.800 |
Why?
| | Complement Membrane Attack Complex | 6 | 2018 | 33 | 0.770 |
Why?
| | Biomarkers | 15 | 2023 | 3471 | 0.770 |
Why?
| | Rhabdomyolysis | 1 | 2021 | 16 | 0.750 |
Why?
| | Cardiolipins | 1 | 2021 | 72 | 0.740 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 348 | 0.740 |
Why?
| | Cyclosporine | 3 | 2019 | 169 | 0.690 |
Why?
| | Immunoglobulin G | 11 | 2023 | 781 | 0.670 |
Why?
| | Otitis Media | 5 | 2016 | 142 | 0.670 |
Why?
| | Hemoglobinuria, Paroxysmal | 2 | 2020 | 5 | 0.650 |
Why?
| | Vascular System Injuries | 1 | 2019 | 64 | 0.650 |
Why?
| | Kidney Failure, Chronic | 3 | 2021 | 490 | 0.650 |
Why?
| | Retinal Pigment Epithelium | 4 | 2017 | 58 | 0.640 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 667 | 0.640 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 224 | 0.630 |
Why?
| | Complement Factor D | 1 | 2018 | 27 | 0.620 |
Why?
| | Pneumococcal Infections | 4 | 2014 | 91 | 0.620 |
Why?
| | Autoantibodies | 10 | 2023 | 1360 | 0.600 |
Why?
| | Doxorubicin | 4 | 2023 | 290 | 0.600 |
Why?
| | Glomerulonephritis, IGA | 1 | 2017 | 7 | 0.600 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 385 | 0.580 |
Why?
| | B-Lymphocytes | 7 | 2022 | 773 | 0.580 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 49 | 0.570 |
Why?
| | Transplantation, Homologous | 3 | 2019 | 397 | 0.570 |
Why?
| | Liver Neoplasms | 1 | 2020 | 521 | 0.540 |
Why?
| | Annexin A2 | 1 | 2016 | 10 | 0.530 |
Why?
| | Renal Insufficiency | 1 | 2018 | 137 | 0.530 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 80 | 0.530 |
Why?
| | Streptococcus pneumoniae | 4 | 2014 | 134 | 0.520 |
Why?
| | Peptide Fragments | 1 | 2019 | 675 | 0.500 |
Why?
| | Pregnancy Complications | 3 | 2018 | 431 | 0.490 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1147 | 0.490 |
Why?
| | Mice, Inbred BALB C | 10 | 2023 | 1168 | 0.490 |
Why?
| | Cardiac Surgical Procedures | 1 | 2019 | 415 | 0.480 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 28 | 0.480 |
Why?
| | Male | 46 | 2022 | 56048 | 0.480 |
Why?
| | Female | 42 | 2023 | 60016 | 0.440 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 488 | 0.430 |
Why?
| | Immune Complex Diseases | 1 | 2012 | 9 | 0.430 |
Why?
| | Liver | 2 | 2020 | 1690 | 0.420 |
Why?
| | Complement C3a | 3 | 2014 | 33 | 0.420 |
Why?
| | Autoimmunity | 5 | 2022 | 822 | 0.410 |
Why?
| | Nanoparticles | 2 | 2013 | 315 | 0.410 |
Why?
| | Receptors, Complement 3b | 6 | 2016 | 81 | 0.410 |
Why?
| | Immunity, Humoral | 1 | 2013 | 112 | 0.410 |
Why?
| | Peptides, Cyclic | 1 | 2014 | 262 | 0.400 |
Why?
| | Molecular Imaging | 1 | 2012 | 52 | 0.400 |
Why?
| | Complement C1q | 3 | 2014 | 38 | 0.390 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2019 | 795 | 0.390 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 112 | 0.390 |
Why?
| | Complement C2 | 2 | 2011 | 6 | 0.380 |
Why?
| | Oxidative Stress | 7 | 2019 | 1093 | 0.350 |
Why?
| | CD55 Antigens | 3 | 2020 | 27 | 0.350 |
Why?
| | Blotting, Western | 7 | 2016 | 1153 | 0.350 |
Why?
| | Ferrosoferric Oxide | 1 | 2010 | 25 | 0.350 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 68 | 0.350 |
Why?
| | Cell Membrane | 4 | 2022 | 683 | 0.350 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 285 | 0.340 |
Why?
| | Plasmodium falciparum | 3 | 1998 | 27 | 0.340 |
Why?
| | Disease Susceptibility | 2 | 2020 | 316 | 0.340 |
Why?
| | Protozoan Proteins | 3 | 1998 | 62 | 0.330 |
Why?
| | Cytokines | 5 | 2019 | 1853 | 0.320 |
Why?
| | Signal Transduction | 9 | 2020 | 4541 | 0.320 |
Why?
| | Properdin | 2 | 2020 | 8 | 0.320 |
Why?
| | Diarrhea | 1 | 2009 | 173 | 0.310 |
Why?
| | Antibody Specificity | 2 | 2021 | 176 | 0.310 |
Why?
| | Adult | 13 | 2023 | 30788 | 0.310 |
Why?
| | Epidermolysis Bullosa Acquisita | 3 | 2018 | 6 | 0.310 |
Why?
| | Complement C4 | 5 | 2021 | 26 | 0.300 |
Why?
| | Receptors, Complement 3d | 4 | 2022 | 130 | 0.300 |
Why?
| | Uremia | 2 | 2021 | 14 | 0.300 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2008 | 63 | 0.300 |
Why?
| | Graft Survival | 4 | 2019 | 480 | 0.300 |
Why?
| | Complement C3b Inactivator Proteins | 2 | 2017 | 9 | 0.290 |
Why?
| | Phagocytosis | 4 | 2023 | 355 | 0.290 |
Why?
| | Metabolomics | 4 | 2019 | 538 | 0.290 |
Why?
| | Podocytes | 2 | 2020 | 44 | 0.290 |
Why?
| | Chemokines, CXC | 1 | 2007 | 58 | 0.280 |
Why?
| | Kidney Tubules, Proximal | 2 | 2016 | 113 | 0.280 |
Why?
| | Adaptive Immunity | 2 | 2019 | 157 | 0.280 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2007 | 114 | 0.270 |
Why?
| | Pilot Projects | 3 | 2021 | 1384 | 0.270 |
Why?
| | Flow Cytometry | 4 | 2022 | 1083 | 0.270 |
Why?
| | Cells, Cultured | 6 | 2019 | 3914 | 0.270 |
Why?
| | Cardiopulmonary Bypass | 1 | 2008 | 176 | 0.270 |
Why?
| | Protein Binding | 6 | 2019 | 1917 | 0.270 |
Why?
| | Immune System Diseases | 1 | 2006 | 35 | 0.260 |
Why?
| | Immunohistochemistry | 5 | 2016 | 1642 | 0.260 |
Why?
| | Chemokines | 1 | 2007 | 214 | 0.260 |
Why?
| | NF-kappa B | 3 | 2016 | 639 | 0.260 |
Why?
| | Organ Specificity | 3 | 2020 | 273 | 0.250 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 414 | 0.250 |
Why?
| | Cell Line | 6 | 2017 | 2651 | 0.250 |
Why?
| | Biopsy | 3 | 2019 | 1056 | 0.250 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2005 | 22 | 0.250 |
Why?
| | Child | 11 | 2023 | 18502 | 0.250 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 21 | 0.240 |
Why?
| | Fetal Death | 1 | 2005 | 49 | 0.240 |
Why?
| | Caspases | 1 | 2006 | 245 | 0.240 |
Why?
| | Disease Progression | 4 | 2017 | 2423 | 0.240 |
Why?
| | Immunity, Innate | 6 | 2017 | 731 | 0.240 |
Why?
| | Chromatography, Liquid | 2 | 2016 | 347 | 0.240 |
Why?
| | Complement C3-C5 Convertases | 3 | 2016 | 19 | 0.230 |
Why?
| | Macular Degeneration | 3 | 2012 | 152 | 0.230 |
Why?
| | Antibodies, Protozoan | 3 | 1998 | 29 | 0.230 |
Why?
| | Middle Aged | 10 | 2022 | 27069 | 0.230 |
Why?
| | Rats | 8 | 2021 | 5033 | 0.230 |
Why?
| | Prognosis | 5 | 2022 | 3343 | 0.220 |
Why?
| | Receptors, Angiotensin | 1 | 2003 | 10 | 0.220 |
Why?
| | Mice, Inbred MRL lpr | 4 | 2022 | 38 | 0.220 |
Why?
| | Case-Control Studies | 2 | 2021 | 3037 | 0.210 |
Why?
| | Tacrolimus | 2 | 2014 | 143 | 0.210 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2003 | 77 | 0.210 |
Why?
| | Ischemia | 3 | 2015 | 363 | 0.210 |
Why?
| | Proteomics | 4 | 2018 | 859 | 0.210 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 180 | 0.200 |
Why?
| | Allografts | 2 | 2019 | 127 | 0.200 |
Why?
| | Lymphoid Tissue | 1 | 2022 | 63 | 0.200 |
Why?
| | CD59 Antigens | 3 | 2011 | 21 | 0.200 |
Why?
| | Antigens, Protozoan | 2 | 1998 | 19 | 0.190 |
Why?
| | Glutamic Acid | 1 | 2023 | 213 | 0.190 |
Why?
| | Organic Anion Transporters | 1 | 2021 | 15 | 0.190 |
Why?
| | Apoptosis | 2 | 2011 | 2377 | 0.190 |
Why?
| | Myoglobin | 1 | 2021 | 14 | 0.190 |
Why?
| | Protein Processing, Post-Translational | 3 | 2023 | 401 | 0.190 |
Why?
| | Immune System | 1 | 2022 | 173 | 0.190 |
Why?
| | Malaria, Falciparum | 2 | 1998 | 25 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 83 | 0.190 |
Why?
| | Choroidal Neovascularization | 2 | 2013 | 44 | 0.190 |
Why?
| | Aged | 7 | 2021 | 19294 | 0.190 |
Why?
| | Proteinuria | 3 | 2012 | 78 | 0.190 |
Why?
| | Paraffin Embedding | 1 | 2021 | 21 | 0.190 |
Why?
| | Formaldehyde | 1 | 2021 | 47 | 0.190 |
Why?
| | Frozen Sections | 1 | 2021 | 23 | 0.190 |
Why?
| | Albuminuria | 2 | 2015 | 164 | 0.180 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2020 | 20 | 0.180 |
Why?
| | Anemia, Hemolytic | 1 | 2020 | 19 | 0.180 |
Why?
| | Treatment Outcome | 3 | 2021 | 9162 | 0.180 |
Why?
| | Dendritic Cells | 2 | 2022 | 438 | 0.180 |
Why?
| | Staining and Labeling | 1 | 2021 | 139 | 0.180 |
Why?
| | Up-Regulation | 3 | 2019 | 820 | 0.170 |
Why?
| | Critical Illness | 2 | 2023 | 645 | 0.170 |
Why?
| | T-Lymphocytes | 5 | 2022 | 1756 | 0.170 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 11 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2012 | 503 | 0.170 |
Why?
| | Urinalysis | 1 | 2019 | 62 | 0.170 |
Why?
| | Transplantation, Heterologous | 1 | 2019 | 187 | 0.160 |
Why?
| | Sepsis | 2 | 2016 | 515 | 0.160 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 169 | 0.160 |
Why?
| | Iodine Radioisotopes | 1 | 2019 | 126 | 0.160 |
Why?
| | Complement C4a | 1 | 2018 | 6 | 0.160 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2586 | 0.160 |
Why?
| | North America | 1 | 2019 | 261 | 0.160 |
Why?
| | Complement C5 | 3 | 2020 | 74 | 0.160 |
Why?
| | Vascular Remodeling | 1 | 2020 | 155 | 0.150 |
Why?
| | Lung | 5 | 2019 | 3673 | 0.150 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 8 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 930 | 0.150 |
Why?
| | Erythrocytes | 2 | 2020 | 589 | 0.150 |
Why?
| | Adolescent | 7 | 2021 | 17922 | 0.150 |
Why?
| | Granulocytes | 2 | 2016 | 78 | 0.150 |
Why?
| | HLA Antigens | 1 | 2019 | 223 | 0.150 |
Why?
| | Organelles | 1 | 1998 | 51 | 0.150 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 36 | 0.150 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 606 | 0.150 |
Why?
| | Cyclophilins | 1 | 2017 | 29 | 0.150 |
Why?
| | Brain Injuries | 3 | 2007 | 451 | 0.150 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 26 | 0.150 |
Why?
| | Gene Expression | 6 | 2017 | 1436 | 0.140 |
Why?
| | Cell Differentiation | 2 | 2022 | 1700 | 0.140 |
Why?
| | Brachial Artery | 1 | 2018 | 173 | 0.140 |
Why?
| | Diethylhexyl Phthalate | 1 | 2017 | 9 | 0.140 |
Why?
| | Blood Pressure | 1 | 2003 | 1539 | 0.140 |
Why?
| | Lipopolysaccharides | 3 | 2015 | 826 | 0.140 |
Why?
| | Macrophages | 3 | 2013 | 1284 | 0.140 |
Why?
| | Interferon-beta | 2 | 2007 | 79 | 0.140 |
Why?
| | Choroiditis | 1 | 2016 | 6 | 0.140 |
Why?
| | Prospective Studies | 4 | 2023 | 6276 | 0.140 |
Why?
| | Bleomycin | 1 | 2018 | 232 | 0.140 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 60 | 0.140 |
Why?
| | Cell Aggregation | 1 | 2016 | 24 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 941 | 0.140 |
Why?
| | Arthritis, Experimental | 2 | 2009 | 133 | 0.140 |
Why?
| | Tuberculosis | 1 | 2019 | 244 | 0.130 |
Why?
| | Phenols | 1 | 2017 | 82 | 0.130 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 271 | 0.130 |
Why?
| | Collagen Type VII | 3 | 2018 | 13 | 0.130 |
Why?
| | MicroRNAs | 1 | 2022 | 607 | 0.130 |
Why?
| | Mucin-5B | 1 | 2018 | 185 | 0.130 |
Why?
| | Ear, Middle | 3 | 2012 | 89 | 0.130 |
Why?
| | Complement C5b | 1 | 2015 | 4 | 0.130 |
Why?
| | Interferon-alpha | 2 | 2007 | 186 | 0.130 |
Why?
| | Carboxypeptidases | 1 | 2015 | 14 | 0.130 |
Why?
| | Inflammation Mediators | 3 | 2019 | 479 | 0.130 |
Why?
| | Immunoprecipitation | 1 | 2016 | 154 | 0.130 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 5 | 0.130 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 8 | 0.130 |
Why?
| | Vasodilation | 1 | 2018 | 412 | 0.130 |
Why?
| | Hypersensitivity, Delayed | 1 | 2015 | 52 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 400 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 97 | 0.130 |
Why?
| | Vaccinia virus | 1 | 2015 | 28 | 0.130 |
Why?
| | Fibroblasts | 1 | 2020 | 839 | 0.120 |
Why?
| | Ultrasonography | 1 | 2018 | 642 | 0.120 |
Why?
| | Analysis of Variance | 2 | 2010 | 1230 | 0.120 |
Why?
| | Hypertension | 1 | 2003 | 1064 | 0.120 |
Why?
| | Complement Fixation Tests | 1 | 2014 | 6 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 136 | 0.120 |
Why?
| | Recombinant Proteins | 3 | 2015 | 1243 | 0.120 |
Why?
| | Abortion, Spontaneous | 2 | 2006 | 92 | 0.120 |
Why?
| | Eustachian Tube | 1 | 2014 | 4 | 0.120 |
Why?
| | Shiga Toxin 2 | 1 | 2014 | 1 | 0.120 |
Why?
| | Edema | 1 | 2015 | 119 | 0.120 |
Why?
| | Mast Cells | 1 | 2015 | 117 | 0.120 |
Why?
| | Immunoglobulins | 2 | 2020 | 147 | 0.110 |
Why?
| | Neutrophils | 2 | 2013 | 1172 | 0.110 |
Why?
| | Mesangial Cells | 1 | 2013 | 2 | 0.110 |
Why?
| | Models, Immunological | 2 | 2012 | 92 | 0.110 |
Why?
| | Orthomyxoviridae Infections | 1 | 2014 | 55 | 0.110 |
Why?
| | Aquaporins | 2 | 2003 | 8 | 0.110 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 297 | 0.110 |
Why?
| | Mycophenolic Acid | 1 | 2014 | 81 | 0.110 |
Why?
| | Cricetulus | 2 | 2010 | 99 | 0.110 |
Why?
| | Recurrence | 1 | 2016 | 953 | 0.110 |
Why?
| | CHO Cells | 2 | 2010 | 140 | 0.110 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 383 | 0.110 |
Why?
| | Blood Platelets | 1 | 2016 | 350 | 0.110 |
Why?
| | Cricetinae | 2 | 2010 | 260 | 0.110 |
Why?
| | Pregnancy | 4 | 2018 | 5552 | 0.110 |
Why?
| | Acute Disease | 3 | 2014 | 914 | 0.110 |
Why?
| | Genetic Variation | 1 | 2018 | 880 | 0.110 |
Why?
| | Genotype | 1 | 2018 | 1787 | 0.110 |
Why?
| | Serum | 1 | 2013 | 57 | 0.110 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 82 | 0.110 |
Why?
| | Lymphocyte Activation | 5 | 2022 | 1057 | 0.110 |
Why?
| | Sirolimus | 1 | 2014 | 192 | 0.100 |
Why?
| | Skin | 2 | 2015 | 662 | 0.100 |
Why?
| | Amino Acids | 1 | 2016 | 454 | 0.100 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 116 | 0.100 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 173 | 0.100 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 30 | 0.100 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2013 | 50 | 0.100 |
Why?
| | Mass Spectrometry | 1 | 2016 | 645 | 0.100 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 357 | 0.100 |
Why?
| | Drug Monitoring | 1 | 2013 | 184 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 372 | 0.100 |
Why?
| | Rhadinovirus | 1 | 2012 | 16 | 0.100 |
Why?
| | Rituximab | 1 | 2013 | 149 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 616 | 0.100 |
Why?
| | Acute Lung Injury | 1 | 2015 | 300 | 0.100 |
Why?
| | Tumor Virus Infections | 1 | 2012 | 41 | 0.100 |
Why?
| | Mitochondria | 1 | 2017 | 750 | 0.100 |
Why?
| | Myocytes, Cardiac | 2 | 2013 | 457 | 0.100 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2018 | 511 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 965 | 0.100 |
Why?
| | Feasibility Studies | 2 | 2015 | 748 | 0.100 |
Why?
| | Bronchial Hyperreactivity | 1 | 2011 | 96 | 0.100 |
Why?
| | Spleen | 1 | 2013 | 492 | 0.100 |
Why?
| | Extracellular Fluid | 1 | 2011 | 32 | 0.090 |
Why?
| | Adenocarcinoma | 1 | 2017 | 799 | 0.090 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 138 | 0.090 |
Why?
| | Plasma Exchange | 1 | 2010 | 12 | 0.090 |
Why?
| | Down-Regulation | 4 | 2020 | 601 | 0.090 |
Why?
| | Tissue Distribution | 3 | 2019 | 324 | 0.090 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 119 | 0.090 |
Why?
| | Blister | 2 | 2008 | 43 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1357 | 0.090 |
Why?
| | Membrane Cofactor Protein | 1 | 2010 | 12 | 0.090 |
Why?
| | Blood Bactericidal Activity | 1 | 2010 | 36 | 0.090 |
Why?
| | Opsonin Proteins | 1 | 2010 | 25 | 0.090 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 112 | 0.090 |
Why?
| | Dextrans | 1 | 2010 | 74 | 0.090 |
Why?
| | Host-Pathogen Interactions | 1 | 2012 | 296 | 0.080 |
Why?
| | Collagen Type II | 1 | 2009 | 48 | 0.080 |
Why?
| | Time Factors | 4 | 2015 | 6171 | 0.080 |
Why?
| | Microbial Viability | 1 | 2010 | 79 | 0.080 |
Why?
| | Osteoarthritis | 1 | 2011 | 173 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2393 | 0.080 |
Why?
| | Antibody Formation | 1 | 2010 | 273 | 0.080 |
Why?
| | RNA, Messenger | 6 | 2022 | 2574 | 0.080 |
Why?
| | Cell Hypoxia | 1 | 2010 | 220 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2020 | 1754 | 0.080 |
Why?
| | Image Enhancement | 1 | 2010 | 180 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2017 | 1078 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 402 | 0.080 |
Why?
| | Young Adult | 2 | 2021 | 10518 | 0.080 |
Why?
| | Bacillus cereus | 1 | 2008 | 5 | 0.080 |
Why?
| | Liver Regeneration | 1 | 2008 | 32 | 0.080 |
Why?
| | Neurons | 2 | 2006 | 1298 | 0.080 |
Why?
| | Allergens | 1 | 2011 | 418 | 0.080 |
Why?
| | Blood-Retinal Barrier | 1 | 2008 | 13 | 0.080 |
Why?
| | Hemolysis | 2 | 2020 | 146 | 0.080 |
Why?
| | Bacteremia | 1 | 2010 | 159 | 0.080 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2007 | 22 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2011 | 1537 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 4 | 2010 | 2129 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 66 | 0.070 |
Why?
| | Binding Sites | 3 | 2016 | 1177 | 0.070 |
Why?
| | Chemokine CXCL2 | 1 | 2007 | 38 | 0.070 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2009 | 158 | 0.070 |
Why?
| | Chemokine CXCL1 | 1 | 2007 | 66 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2007 | 141 | 0.070 |
Why?
| | Cloning, Molecular | 2 | 2017 | 523 | 0.070 |
Why?
| | Kidney Concentrating Ability | 2 | 2003 | 3 | 0.070 |
Why?
| | Poly I-C | 1 | 2006 | 52 | 0.070 |
Why?
| | Leukocytes | 1 | 2008 | 281 | 0.070 |
Why?
| | Immunization, Passive | 1 | 2006 | 80 | 0.070 |
Why?
| | Renal Circulation | 1 | 2006 | 53 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2009 | 369 | 0.070 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 63 | 0.070 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 699 | 0.060 |
Why?
| | Mice, Transgenic | 3 | 2017 | 1970 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 3 | 2006 | 2262 | 0.060 |
Why?
| | Nephrectomy | 1 | 2006 | 150 | 0.060 |
Why?
| | Mutation | 1 | 2016 | 3364 | 0.060 |
Why?
| | Antigens, Surface | 1 | 2006 | 151 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2019 | 477 | 0.060 |
Why?
| | Complement C6 | 2 | 2018 | 9 | 0.060 |
Why?
| | Lung Transplantation | 1 | 2007 | 246 | 0.060 |
Why?
| | Nitric Oxide | 1 | 2010 | 832 | 0.060 |
Why?
| | Membrane Transport Proteins | 2 | 2003 | 137 | 0.060 |
Why?
| | Basement Membrane | 1 | 2005 | 29 | 0.060 |
Why?
| | Placental Insufficiency | 1 | 2006 | 102 | 0.060 |
Why?
| | Neuroprotective Agents | 1 | 2006 | 105 | 0.060 |
Why?
| | Random Allocation | 1 | 2006 | 337 | 0.060 |
Why?
| | Probability | 1 | 2006 | 294 | 0.060 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 16 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2207 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2005 | 51 | 0.060 |
Why?
| | Brain | 2 | 2006 | 2373 | 0.060 |
Why?
| | Pulmonary Fibrosis | 1 | 2007 | 330 | 0.060 |
Why?
| | Age Factors | 1 | 2011 | 2911 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2010 | 1024 | 0.060 |
Why?
| | Lung Injury | 1 | 2006 | 199 | 0.060 |
Why?
| | Collagen | 1 | 2006 | 416 | 0.060 |
Why?
| | Toll-Like Receptors | 2 | 2016 | 166 | 0.060 |
Why?
| | Receptors, Cell Surface | 1 | 2006 | 356 | 0.060 |
Why?
| | Myocardium | 1 | 2009 | 926 | 0.060 |
Why?
| | Compulsive Behavior | 1 | 2003 | 5 | 0.060 |
Why?
| | Drinking Behavior | 1 | 2003 | 10 | 0.060 |
Why?
| | Antiphospholipid Syndrome | 1 | 2003 | 26 | 0.060 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2003 | 21 | 0.060 |
Why?
| | Annexins | 1 | 2023 | 3 | 0.060 |
Why?
| | Racemethionine | 1 | 2023 | 3 | 0.060 |
Why?
| | Energy Metabolism | 2 | 2019 | 715 | 0.060 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2003 | 9 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 43 | 0.050 |
Why?
| | Complement C9 | 1 | 2003 | 5 | 0.050 |
Why?
| | Blood Urea Nitrogen | 1 | 2003 | 51 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 346 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 1919 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2023 | 198 | 0.050 |
Why?
| | Cartilage, Articular | 1 | 2006 | 291 | 0.050 |
Why?
| | Hypothyroidism | 1 | 2003 | 65 | 0.050 |
Why?
| | Sodium | 1 | 2003 | 183 | 0.050 |
Why?
| | Methionine | 1 | 2023 | 145 | 0.050 |
Why?
| | Carrier Proteins | 2 | 2003 | 701 | 0.050 |
Why?
| | Neutralization Tests | 2 | 2015 | 63 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 32 | 0.050 |
Why?
| | HLA-D Antigens | 1 | 2022 | 34 | 0.050 |
Why?
| | Ubiquitination | 1 | 2022 | 86 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2022 | 244 | 0.050 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 64 | 0.050 |
Why?
| | Fetal Growth Retardation | 1 | 2006 | 466 | 0.050 |
Why?
| | Cholecalciferol | 1 | 2021 | 47 | 0.050 |
Why?
| | Phospholipase D | 1 | 2020 | 7 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2022 | 189 | 0.050 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2022 | 139 | 0.050 |
Why?
| | Antibodies, Blocking | 1 | 2020 | 32 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 2000 | 0.040 |
Why?
| | Child, Preschool | 2 | 2015 | 9136 | 0.040 |
Why?
| | Cell Line, Transformed | 1 | 2020 | 133 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2022 | 353 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2003 | 962 | 0.040 |
Why?
| | Particle Size | 1 | 2021 | 319 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2013 | 549 | 0.040 |
Why?
| | Cell Movement | 2 | 2015 | 867 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 90 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2020 | 93 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 2751 | 0.040 |
Why?
| | Dinoprost | 1 | 2019 | 31 | 0.040 |
Why?
| | Mice, Congenic | 2 | 2010 | 21 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 140 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 77 | 0.040 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 161 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 608 | 0.040 |
Why?
| | Immunoblotting | 2 | 2010 | 281 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 170 | 0.040 |
Why?
| | Brefeldin A | 1 | 1998 | 15 | 0.040 |
Why?
| | Cyclopentanes | 1 | 1998 | 15 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 302 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1998 | 52 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2020 | 370 | 0.040 |
Why?
| | Immunity, Active | 1 | 1998 | 9 | 0.040 |
Why?
| | A549 Cells | 1 | 2018 | 51 | 0.040 |
Why?
| | Aotidae | 1 | 1998 | 7 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1998 | 44 | 0.040 |
Why?
| | Parasitemia | 1 | 1998 | 9 | 0.040 |
Why?
| | Immunodominant Epitopes | 1 | 1998 | 26 | 0.040 |
Why?
| | Self Tolerance | 1 | 2017 | 28 | 0.040 |
Why?
| | Vitamin D | 1 | 2021 | 341 | 0.040 |
Why?
| | Macrolides | 1 | 1998 | 56 | 0.040 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 399 | 0.040 |
Why?
| | Ligands | 1 | 2019 | 569 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 75 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 622 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1998 | 352 | 0.040 |
Why?
| | Immunomodulation | 1 | 2017 | 85 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 147 | 0.040 |
Why?
| | Germinal Center | 1 | 2017 | 49 | 0.040 |
Why?
| | DNA Damage | 1 | 2019 | 357 | 0.030 |
Why?
| | Recombination, Genetic | 1 | 1998 | 177 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 165 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1137 | 0.030 |
Why?
| | Infant | 1 | 2009 | 7978 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2017 | 93 | 0.030 |
Why?
| | Epithelial Sodium Channels | 1 | 2016 | 12 | 0.030 |
Why?
| | Biological Transport, Active | 1 | 2016 | 71 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 13 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 178 | 0.030 |
Why?
| | Potassium Channels | 1 | 2016 | 121 | 0.030 |
Why?
| | Sulfones | 1 | 2016 | 98 | 0.030 |
Why?
| | Nitriles | 1 | 2016 | 152 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 306 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2015 | 32 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 704 | 0.030 |
Why?
| | Smallpox Vaccine | 1 | 2015 | 22 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2015 | 51 | 0.030 |
Why?
| | Sunburn | 1 | 2015 | 25 | 0.030 |
Why?
| | Vero Cells | 1 | 2015 | 65 | 0.030 |
Why?
| | Fetus | 2 | 2012 | 702 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 202 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 214 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 499 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 209 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 245 | 0.030 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 5 | 0.030 |
Why?
| | Pyridones | 1 | 2015 | 125 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 1739 | 0.030 |
Why?
| | Cecum | 1 | 2013 | 32 | 0.030 |
Why?
| | Hypoxia | 1 | 2020 | 937 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1122 | 0.030 |
Why?
| | Water Deprivation | 2 | 2003 | 8 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 567 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 317 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2013 | 271 | 0.030 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 90 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2790 | 0.030 |
Why?
| | International Cooperation | 1 | 2013 | 174 | 0.030 |
Why?
| | Coinfection | 1 | 2014 | 120 | 0.030 |
Why?
| | Complement C4b-Binding Protein | 1 | 2012 | 3 | 0.030 |
Why?
| | Ion Transport | 1 | 2012 | 55 | 0.030 |
Why?
| | Otitis | 1 | 2012 | 9 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 101 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2014 | 139 | 0.030 |
Why?
| | Gene Deletion | 1 | 2014 | 355 | 0.030 |
Why?
| | Gluconeogenesis | 1 | 2012 | 60 | 0.030 |
Why?
| | Glucose | 1 | 2017 | 904 | 0.030 |
Why?
| | Demyelinating Diseases | 1 | 2013 | 75 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 301 | 0.030 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2011 | 24 | 0.020 |
Why?
| | Synovial Fluid | 1 | 2011 | 57 | 0.020 |
Why?
| | Phosphates | 1 | 2012 | 160 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2012 | 368 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2015 | 527 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 344 | 0.020 |
Why?
| | Ovalbumin | 1 | 2011 | 166 | 0.020 |
Why?
| | Glycolysis | 1 | 2012 | 224 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2012 | 149 | 0.020 |
Why?
| | Joints | 1 | 2011 | 84 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 390 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 157 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 318 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 250 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2010 | 96 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 483 | 0.020 |
Why?
| | Glycosylation | 1 | 2010 | 133 | 0.020 |
Why?
| | Epithelium | 1 | 2011 | 297 | 0.020 |
Why?
| | Cartilage | 1 | 2011 | 182 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 267 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 412 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1219 | 0.020 |
Why?
| | Chondrocytes | 1 | 2011 | 199 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 408 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2010 | 209 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1998 | 1485 | 0.020 |
Why?
| | Drug Combinations | 1 | 2009 | 289 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1825 | 0.020 |
Why?
| | Autoantigens | 1 | 2011 | 398 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1001 | 0.020 |
Why?
| | Receptors, Interleukin-8B | 1 | 2007 | 23 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2008 | 45 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 804 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1044 | 0.020 |
Why?
| | Biomedical Research | 1 | 2013 | 589 | 0.020 |
Why?
| | Permeability | 1 | 2008 | 150 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 794 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 88 | 0.020 |
Why?
| | Tight Junctions | 1 | 2008 | 68 | 0.020 |
Why?
| | Mannose-Binding Lectin | 1 | 2007 | 21 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 138 | 0.020 |
Why?
| | Vaccination | 1 | 2015 | 1210 | 0.020 |
Why?
| | Syndrome | 1 | 2007 | 339 | 0.020 |
Why?
| | Cattle | 1 | 2009 | 935 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 746 | 0.020 |
Why?
| | Rodentia | 1 | 2006 | 44 | 0.020 |
Why?
| | Placenta Diseases | 1 | 2006 | 13 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 4448 | 0.020 |
Why?
| | Antibodies, Antinuclear | 1 | 2006 | 60 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2114 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2006 | 47 | 0.020 |
Why?
| | Protein Transport | 1 | 2008 | 400 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 68 | 0.020 |
Why?
| | Head Injuries, Closed | 1 | 2006 | 48 | 0.020 |
Why?
| | Synovial Membrane | 1 | 2006 | 75 | 0.020 |
Why?
| | fas Receptor | 1 | 2006 | 93 | 0.020 |
Why?
| | Trachea | 1 | 2007 | 233 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2006 | 111 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 214 | 0.020 |
Why?
| | Models, Molecular | 1 | 2010 | 1390 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2012 | 2824 | 0.020 |
Why?
| | Cell Death | 1 | 2006 | 326 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2006 | 299 | 0.020 |
Why?
| | Phenotype | 1 | 2012 | 2839 | 0.010 |
Why?
| | Swine | 1 | 2006 | 706 | 0.010 |
Why?
| | Peptides | 1 | 2009 | 864 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2006 | 278 | 0.010 |
Why?
| | Monocytes | 1 | 2006 | 507 | 0.010 |
Why?
| | Receptors, Vasopressin | 1 | 2003 | 18 | 0.010 |
Why?
| | Aquaporin 2 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 3 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 6 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 1 | 1 | 2003 | 3 | 0.010 |
Why?
| | Kidney Medulla | 1 | 2003 | 29 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2006 | 677 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 178 | 0.010 |
Why?
| | Cell Survival | 1 | 2006 | 1024 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2006 | 472 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1646 | 0.010 |
Why?
| | Aquaporin 4 | 1 | 2003 | 86 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2353 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 1870 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2009 | 931 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2118 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2003 | 431 | 0.010 |
Why?
| | Placenta | 1 | 2006 | 624 | 0.010 |
Why?
| | Asthma | 1 | 2011 | 2066 | 0.010 |
Why?
| | Transients and Migrants | 1 | 1998 | 22 | 0.010 |
Why?
| | Brazil | 1 | 1998 | 93 | 0.010 |
Why?
| | Age Distribution | 1 | 1998 | 341 | 0.010 |
Why?
|
|
Thurman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|